Using CSF Biomarkers to Diagnose Alzheimer's Disease
Author Information
Author(s): Eratne Dhamidhu, Collins Steven, Nestor Peter J., Pond Dimity, Velakoulis Dennis, Yates Mark, Masters Colin L.
Primary Institution: The Royal Melbourne Hospital
Hypothesis
The study explores the role and benefits of cerebrospinal fluid (CSF) biomarkers in diagnosing Alzheimer's disease (AD) in Australia.
Conclusion
CSF biomarker testing is a safe and cost-effective method that can provide a more accurate diagnosis of Alzheimer's disease earlier in the disease course.
Supporting Evidence
- CSF biomarkers provide a higher degree of sensitivity and specificity compared to clinical diagnosis alone.
- CSF biomarker testing is a safe and cost-effective diagnostic method.
- Early diagnosis of Alzheimer's disease can empower patients and their carers to plan for the future.
- CSF biomarker testing can help exclude Alzheimer's disease and assist with differential diagnosis of cognitive impairment.
- CSF biomarker testing is currently the only clinically validated biofluid diagnostic test for Alzheimer's disease available in Australia.
Takeaway
Doctors can use special tests on spinal fluid to help find out if someone has Alzheimer's disease, which can help them get the right care sooner.
Methodology
The authors conducted a literature search via PubMed, Google Scholar, and Cochrane Review to gather evidence on CSF biomarkers for diagnosing Alzheimer's disease.
Potential Biases
Potential biases include regional access disparities and clinician hesitance due to misconceptions about the lumbar puncture procedure.
Limitations
The use of CSF biomarkers in clinical practice is limited due to access challenges, perceived invasiveness of lumbar puncture, and clinician confidence in interpreting results.
Participant Demographics
The article discusses the context of Alzheimer's disease diagnosis in Australia, but specific demographics of participants are not provided.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website